SecurityGTIM / Good Times Restaurants, Inc. (382140879)
President, CEOHOBACK BOYD E
IndustryRestaurants, Dining, and Eating Places
Institutional Owners19
Institutional Shares3,443,737 - 27.61%
Common Shares Outstanding12,471,765 shares (as of 2018-06-26)
Institutional Value$ 11,238,000 USD

Institutional Stock Ownership and Shareholders

Good Times Restaurants, Inc. (NASDAQ:GTIM) has 19 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 3,443,737 shares. Largest shareholders include Delta Partners Llc, Manatuck Hill Partners, LLC, Vanguard Group Inc, Granite Point Capital Management, L.P., Renaissance Technologies LLC, BlackRock Inc., Geode Capital Management, Llc, Wall Street Associates, Deutsche Bank Ag\, and BlackRock Fund Advisors.
Good Times Restaurants, Inc. (NASDAQ:GTIM) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-08-14 13F-HR DEUTSCHE BANK AG\ 45,755 40,543 -11.39 139 152 9.35
2018-08-14 13F-HR VANGUARD GROUP INC 256,374 269,030 4.94 782 1,009 29.03
2017-01-18 13F-HR WALL STREET ASSOCIATES 51,900 51,900 0.00 175 163 -6.86
2017-02-10 13F-HR BlackRock Investment Management, LLC 1,900 1,900 0.00 6 6 0.00
2018-08-13 13F-HR Manatuck Hill Partners, LLC 1,041,400 1,041,400 0.00 3,176 3,905 22.95
2018-08-02 13F-HR BUCKHEAD CAPITAL MANAGEMENT LLC 12,700 0 -100.00 39 0 -100.00
2018-08-14 13F-HR GEODE CAPITAL MANAGEMENT, LLC 56,983 56,983 0.00 173 213 23.12
2018-08-15 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 15,000 15,000 0.00 46 56 21.74
2018-08-14 13F-HR MORGAN STANLEY 14,023 14,060 0.26 43 53 23.26
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 25,936 25,936 0.00 87 82 -5.75
2017-02-09 SC 13G/A Wellington Trust Company, National Association Multiple Common Trust Funds Trust, Micro Cap Equity Portfolio 614,500 0 -100.00 0 -100.00
2018-08-14 13F-HR UBS Group AG 1,420 0 -100.00 4 0 -100.00
2018-08-10 13F-HR DIMENSIONAL FUND ADVISORS LP 16,162 17,293 7.00 49 65 32.65
2018-08-14 13F-HR MACQUARIE GROUP LTD 36,461 32,461 -10.97 111 122 9.91
2018-08-13 13F-HR Renaissance Technologies LLC 106,000 323
2018-02-14 13F-HR DELTA PARTNERS LLC 2,271,226 1,392,109 -38.71 6,132 3,689 -39.84
2018-08-01 13F-HR WELLS FARGO & COMPANY/MN 0 133 0 0
2018-08-09 13F-HR BlackRock Inc. 67,052 65,283 -2.64 205 244 19.02
2017-02-10 13F-HR BlackRock Fund Advisors 33,271 34,123 2.56 112 107 -4.46
2018-08-13 13F-HR Granite Point Capital Management, L.P. 273,050 258,050 -5.49 833 968 16.21
2018-08-14 13F-HR BANK OF AMERICA CORP /DE/ 0 141 0 1
2018-09-18 13F-HR/A NORTHERN TRUST CORP 22,757 21,392 -6.00 69 80 15.94

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

17h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Related News Stories

The Zacks Analyst Blog Highlights: Caterpillar, D.R. Horton, Bristol-Myers Squibb, athenahealth and BJ's Restaurants

2018-09-07 zacks
Chicago, IL – September 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caterpillar Inc. (CAT - Free Report) , D.R. Horton, Inc. (DHI - Free Report) , Bristol-Myers Squibb Company (BMY - Free Report) , athenahealth, Inc. (24-0)

The Zacks Analyst Blog Highlights: Chevron, U.S. Bancorp, Kraft Heinz, General Mills and Workday

2018-09-07 zacks
Chicago, IL – September 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Chevron (CVX - Free Report) , U.S. Bancorp (USB - Free Report) , Kraft Heinz (KHC - Free Report) , General Mills (GIS - Free Report) and Workday (WDAY - Free Report) . (27-0)

The Zacks Analyst Blog Highlights: Sony, Honda Motor, ORIX and OBIC

2018-09-07 zacks
Chicago, IL – September 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Sony Corporation (SNE - Free Report) , Honda Motor Co., Ltd. (HMC - Free Report) , ORIX Corporation (IX - Free Report) and OBIC Co. (23-0)

Zacks.com highlights: Delek US Holdings, ArcBest, Verso, DICK's Sporting Goods and Dillard's

2018-09-07 zacks
Chicago, IL – September 7, 2018 - Stocks in this week’s article include: Delek US Holdings, Inc. (DK - Free Report) , ArcBest Corporation (ARCB - Free Report) , Verso Corp. (VRS - Free Report) , DICK’S Sporting Goods Inc. (DKS - Free Report) and Dillard's Inc. (DDS - Free Report) . (21-0)

The Zacks Analyst Blog Highlights: Amazon, Burlington Stores, Target and Dollar General

2018-09-07 zacks
Chicago, IL – September 7, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Amazon (AMZN - Free Report) , Burlington Stores, Inc. (BURL - Free Report) , Target Corp. (TGT - Free Report) and Dollar General Corp. (21-0)

CUSIP: 382140879